Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Lazcluze
Synonyms :
Lazertinib
Class :
Antineoplastics, EGFR Inhibitors
Brand Name :
Lazcluze
Synonyms :
Lazertinib
Class :
Antineoplastics, EGFR Inhibitors
Adult
Tablet
80 mg
240 mg
Not determined
Lazertinib targets and inhibits mutant EGFR forms including T790M mutation in resistance to earlier inhibitors.
It inhibits cell proliferation and survival pathways to reduce tumor growth and tumor death.
Frequency defined:
>50%
All grades
Rash
Nail toxicity
Increased ALT
Infusion-related reaction
Decreased albumin
Increased AST
Decreased platelet count
>10-50%
All grades
Musculoskeletal pain
Increased GGT
Decreased sodium
Decreased white blood cell
Venous thromboembolism
Nausea
Cough
Ocular toxicity
Fatigue
Decreased potassium
Constipation
Increased creatinine
Increased alkaline phosphatase
Stomatitis
Edema
Hemorrhage
Decreased magnesium
Pruritus
Decreased appetite
Decreased neutrophils
Dyspnea
Headache
Vomiting
Pyrexia
Abdominal pain
Conjunctivitis
Grade 3 or 4
Rash
Venous thromboembolism
Nail toxicity
1-10%
All grades
Hemorrhoids
Insomnia
ILD/pneumonitis
Grade 3 or 4
Decreased albumin
Increased ALT
Decreased potassium
Fatigue
Decreased neutrophils
Increased magnesium
Edema
Stomatitis
Decreased sodium
Infusion-related reaction
Decreased calcium, corrected
Musculoskeletal pain
Paresthesia
Decreased hemoglobin
Nausea
Hemorrhage
Decreased appetite
Decreased white blood cell
<1%
Grade 3 or 4
Ocular toxicity
Pruritus
Decreased platelet count
Increased creatinine
Decreased magnesium
Conjunctivitis
Headache
Vomiting
Increased alkaline phosphatase
None
Contraindications:
None
Cautions:
Venous thromboembolic events
Dermatologic toxicity
Interstitial lung disease
Embryo-fetal toxicity
Ocular toxicity
Pregnancy category: Â N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
It targets mutant EGFR binds to cysteine residue in ATP-binding site, which inhibits tyrosine kinase activity. It has lower affinity for wild-type EGFR to reduce toxicities.
Pharmacodynamics:
It inhibits downstream pathways to reduces proliferation and increases apoptosis in cancer cells. It is selective for mutant EGFR over wild type that reduces side effects associated with EGFR inhibition in normal tissues.
Pharmacokinetic:
Absorption:
It is administered orally and has good bioavailability for effective systemic absorption.
Distribution:
It is distributed throughout the body with protein binding 99.2%.
Metabolism:
It is metabolized in the liver with the cytochrome P450 enzyme.
Excretion and elimination:
It has mean half-life of 3.7 days and clearance up to 36.4 L/hr.
It is taken orally in oral dosage form.
Patient information leaflet:
Generic Name: Lazertinib
Why do we use Lazertinib?
Lazertinib is indicated in treatment of advanced or metastatic non-small cell lung cancer.
It is used in combination with other agents to enhance its effectiveness and overcome resistance mechanisms.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
